Remsima SC (Infliximab)
infliximab 120 mg/mL injection, 1 mL pen device · INJECTION · PBS code 12584H
AUTHORITY_REQUIREDWhat it costs
AU$252.4 PBS-determined price per 2 units
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2021-07-01.
- • Repeats: 0.
- • PBS program: GE.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Moderate to severe ulcerative colitis
Balance of supply for Initial treatment - subcutaneous form
Must be treated by a gastroenterologist (code 87); or
Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; or
Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)]; AND
Patient must have received insufficient therapy with this drug under the Initial treatment with subcutaneous form to complete 14 to 16 weeks initial treatment (intravenous and subcutaneous inclusive); AND
The treatment must provide no more than the balance of doses up to 14 to 16 weeks therapy available under Initial treatment - subcutaneous form; AND
Patient must be at least 18 years of age.
Sponsor: Celltrion Healthcare Australia Pty Ltd ABN 66 625 407 105
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.